A detailed history of Centiva Capital, LP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Centiva Capital, LP holds 10,724 shares of DVAX stock, worth $132,548. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,724
Holding current value
$132,548
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $107,776 - $124,505
10,724 New
10,724 $119,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.17 $43,980 - $58,804
-4,465 Reduced 30.75%
10,057 $129,000
Q1 2023

May 15, 2023

BUY
$9.44 - $11.88 $137,087 - $172,521
14,522 New
14,522 $142,000
Q3 2021

Nov 15, 2021

SELL
$9.16 - $19.83 $271,145 - $586,987
-29,601 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$7.25 - $10.99 $214,607 - $325,314
29,601 New
29,601 $292,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.56B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.